B
Competitive
Injectable division · GLP-1 mono
Semaglutide 2.4 mg
Novo Nordisk · Wegovy · once weekly
Approved
Division standing
#4 of 5
Injectable division
← Tolerability cost (bands)% body weight lost →
Mild012% vs placebo
Tolerability: the cost
Mild7% vs 3.1% placebo
AE-discontinuation +3.9 points, at the 2.4 mg weekly. From STEP-1.
Efficacy
12%2.4 mg · placebo-adjusted · 68 wk
STEP-1: 14.9% vs 2.4% placebo, a 12-point gap on the treatment policy estimand.
The drug that opened the era, and still the baseline every newcomer is measured against.
STEP-1 predates the tracker window (first posted 2018), so figures come from the NEJM 2021 paper directly.
Convenience profile: you weigh it, not us
Route
Subcutaneous injection
Frequency
Once weekly
Food / water rule
None
Titration
Five-step escalation over 16 weeks
Storage
Refrigerated (room temperature up to 28 days)
Provenance: every number traces back
TrialSTEP-1 · NCT03548935
Estimandtreatment policy estimand
Populationnon-diabetic obesity
Dose2.4 mg weekly
SourceWilding NEJM 2021
Verdict confirmed5 Jul 2026
Compare Semaglutide 2.4 mg against:RetatrutideTirzepatideCagriSemaSurvodutideOral semaglutideOrforglipron